Skip to main content
. Author manuscript; available in PMC: 2023 Mar 26.
Published in final edited form as: Clin Transplant. 2021 Feb 6;35(3):e14206. doi: 10.1111/ctr.14206

FIGURE 2.

FIGURE 2

A, When stratified for levels of dd-cfDNA below or above the median patients with high levels of dd-cfDNA ≥ 0.12 were significantly more likely to have CAV 63% vs. 35% when compared to those with low levels of dd-cfDNA (p 0.047). CAV—Cardiac allograft vasculopathy; dd-cfDNA—Donor-derived Cell-free DNA. B, Patients with high levels of dd-cfDNA ≥ 0.12 had higher percentage of de-novo DSA formation (25 vs. 3.8%, p 0.033). DSA—Donor-specific antibodies; dd-cfDNA—Donor-derived Cell-free DNA.